-$0.12 Earnings Per Share Expected for Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) This Quarter

Equities analysts predict that Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC – Get Rating) will announce earnings of ($0.12) per share for the current quarter, Zacks reports. Five analysts have issued estimates for Tabula Rasa HealthCare’s earnings. The highest EPS estimate is ($0.05) and the lowest is ($0.17). Tabula Rasa HealthCare posted earnings of ($0.09) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 33.3%. The firm is expected to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Tabula Rasa HealthCare will report full-year earnings of ($0.08) per share for the current financial year, with EPS estimates ranging from ($0.21) to $0.05. For the next year, analysts anticipate that the business will post earnings of $0.07 per share, with EPS estimates ranging from ($0.34) to $0.50. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that follow Tabula Rasa HealthCare.

Tabula Rasa HealthCare (NASDAQ:TRHC – Get Rating) last announced its quarterly earnings data on Thursday, February 24th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The firm had revenue of $85.69 million during the quarter, compared to analysts’ expectations of $85.19 million. Tabula Rasa HealthCare had a negative net margin of 23.86% and a negative return on equity of 61.87%. The company’s revenue for the quarter was up 11.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.53) EPS.

A number of equities analysts recently weighed in on TRHC shares. StockNews.com raised shares of Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a research report on Saturday, April 2nd. Robert W. Baird lowered shares of Tabula Rasa HealthCare from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $24.00 to $11.00 in a report on Tuesday, February 1st. Benchmark reduced their price objective on shares of Tabula Rasa HealthCare from $30.00 to $15.00 and set a “buy” rating on the stock in a report on Wednesday, March 2nd. Zacks Investment Research upgraded shares of Tabula Rasa HealthCare from a “hold” rating to a “buy” rating and set a $6.25 price objective on the stock in a report on Tuesday, March 1st. Finally, SVB Leerink reduced their price objective on shares of Tabula Rasa HealthCare from $23.00 to $11.00 and set a “market perform” rating on the stock in a report on Monday, February 28th. Six analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Tabula Rasa HealthCare currently has a consensus rating of “Hold” and a consensus target price of $14.53.

In other news, COO Michael Greenhalgh sold 2,010 shares of Tabula Rasa HealthCare stock in a transaction dated Friday, January 14th. The shares were sold at an average price of $14.87, for a total value of $29,888.70. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Brian W. Adams sold 1,958 shares of Tabula Rasa HealthCare stock in a transaction dated Wednesday, January 12th. The shares were sold at an average price of $15.68, for a total transaction of $30,701.44. The disclosure for this sale can be found here. In the last ninety days, insiders bought 17,000 shares of company stock worth $97,110 and sold 9,990 shares worth $151,909. 10.20% of the stock is owned by insiders.

Several hedge funds have recently bought and sold shares of the company. Masso Torrence Wealth Management Inc. acquired a new stake in shares of Tabula Rasa HealthCare in the 4th quarter worth approximately $39,000. Emerald Advisers LLC purchased a new position in Tabula Rasa HealthCare in the 4th quarter valued at approximately $72,000. Captrust Financial Advisors increased its stake in Tabula Rasa HealthCare by 3,136.9% in the 3rd quarter. Captrust Financial Advisors now owns 5,794 shares of the company’s stock valued at $152,000 after purchasing an additional 5,615 shares in the last quarter. Advisor Group Holdings Inc. increased its stake in Tabula Rasa HealthCare by 19.6% in the 3rd quarter. Advisor Group Holdings Inc. now owns 6,006 shares of the company’s stock valued at $158,000 after purchasing an additional 983 shares in the last quarter. Finally, Maryland State Retirement & Pension System purchased a new position in Tabula Rasa HealthCare in the 3rd quarter valued at approximately $262,000. Institutional investors own 88.29% of the company’s stock.

NASDAQ TRHC opened at $4.96 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.22 and a debt-to-equity ratio of 6.26. The firm has a market cap of $127.63 million, a PE ratio of -1.46 and a beta of 1.33. The business’s fifty day simple moving average is $6.49 and its 200-day simple moving average is $13.74. Tabula Rasa HealthCare has a 52 week low of $4.25 and a 52 week high of $53.38.

Tabula Rasa HealthCare Company Profile (Get Rating)

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. The company operates in two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx, a cloud-based medication decision-support and e-prescribing platform to access patient medication-related information; and MedWise medication therapy management software, a cloud-based platform designed to aid in the identification and resolution of medication and health-related problems.

Featured Stories